Positive Attributes of Anti-TERT CD4 T-Helper Type 1 Immune Responses in Melanoma.
Journal
The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
15
09
2021
revised:
20
09
2021
accepted:
20
09
2021
pubmed:
21
10
2021
medline:
29
1
2022
entrez:
20
10
2021
Statut:
ppublish
Résumé
Nardin et al's (2021) study on melanoma reports anti-TERT CD4 T helper type (Th) 1 responses in more than half of patients. Besides indicating a trend for improved survival, increased anti-TERT CD4 Th1 responses predicted better outcomes for patients treated with immune checkpoint inhibitors. Thus, harnessing systemic anti-TERT CD4 Th1 responses together with tumor-specific elevation of telomerase can potentially open new avenues for biomarkers and treatment in melanoma.
Identifiants
pubmed: 34666894
pii: S0022-202X(21)02269-7
doi: 10.1016/j.jid.2021.09.005
pii:
doi:
Substances chimiques
Telomerase
EC 2.7.7.49
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
279-281Subventions
Organisme : Wellcome Trust
ID : 110078/Z/15/Z
Pays : United Kingdom
Commentaires et corrections
Type : CommentOn
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.